PMID- 35017371
OWN - NLM
STAT- MEDLINE
DCOM- 20220811
LR  - 20220811
IS  - 1998-4774 (Electronic)
IS  - 0019-509X (Linking)
VI  - 59
IP  - 2
DP  - 2022 Apr-Jun
TI  - Predictive role of neutropenia under crizotinib treatment in ALK-rearranged 
      nonsmall cell lung cancer patients: A single-institution retrospective analysis.
PG  - 251-256
LID - 10.4103/ijc.IJC_71_20 [doi]
AB  - BACKGROUND: Anaplastic lymphoma kinase (ALK)-rearranged nonsmall cell lung cancer 
      (NSCLC) represents a molecular subgroup with high sensitivity to ALK inhibitors. 
      Tyrosine kinase inhibitor crizotinib, an anticancer drug acting as an ALK 
      inhibitor, has shown remarkable response in ALK-positive NSCLC. The aim of our 
      study is to explore the adverse events (AEs) of patients on crizotinib therapy 
      and analyze the predictability of AEs for better survival or response on NSCLC 
      patients. METHODS: The medical records of our ALK-positive metastatic NSCLC 
      patients who applied between years 2013 and 2018 had been reviewed 
      retrospectively. ALK positivity of all patients had been detected by fluorescence 
      in situ hybridization and no other driver mutations were present. Patient 
      demographics, performance status, smoking history, previous treatments, 
      metastatic sites, and AEs were recorded for further analyses. RESULTS: Thirty-six 
      ALK-positive metastatic NSCLC patients were included in the study. Median 
      follow-up was 30.1 months. Median progression-free survival (PFS) for patients 
      who developed hepatic, cardiac, or endocrine toxicities was similar when compared 
      to patients who did not develop. Although there was a numeric median PFS 
      difference between patients who did develop visual disorders (18.4 months) and 
      did not develop visual disorders (15.5 month), this was not regarded as 
      statistically significant. However, median PFS of the patients who developed 
      neutropenia upon crizotinib treatment (31.9 months) was found to be more 
      favorable than the patients with normal neutrophil counts (12.8 months) (P = 
      0.026). CONCLUSION: Neutropenia under crizotinib treatment was found to be 
      associated with improved PFS suggesting that neutropenia might be an important 
      determinant in treatment and survival strategies.
FAU - Gursoy, Pinar
AU  - Gursoy P
AD  - Department of Medical Oncology, Ege University School of Medicine, Tulay Aktas 
      Oncology Hospital, Izmir, Turkey.
FAU - Cakar, Burcu
AU  - Cakar B
AD  - Department of Medical Oncology, Ege University School of Medicine, Tulay Aktas 
      Oncology Hospital, Izmir, Turkey.
FAU - Nart, Deniz
AU  - Nart D
AD  - Depatment of Pathology, Ege University School of Medicine, Izmir, Turkey.
FAU - Goker, Erdem
AU  - Goker E
AD  - Department of Medical Oncology, Ege University School of Medicine, Tulay Aktas 
      Oncology Hospital, Izmir, Turkey.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Cancer
JT  - Indian journal of cancer
JID - 0112040
RN  - 0 (Protein Kinase Inhibitors)
RN  - 53AH36668S (Crizotinib)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Anaplastic Lymphoma Kinase/genetics
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/pathology
MH  - Crizotinib/adverse effects
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Lung Neoplasms/drug therapy/genetics/pathology
MH  - *Neutropenia/chemically induced/drug therapy
MH  - Protein Kinase Inhibitors/adverse effects
MH  - Receptor Protein-Tyrosine Kinases/genetics
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Anaplastic lymphoma kinase
OT  - neutropenia
OT  - nonsmall cell lung cancer
COIS- None
EDAT- 2022/01/13 06:00
MHDA- 2022/08/12 06:00
CRDT- 2022/01/12 06:13
PHST- 2022/01/13 06:00 [pubmed]
PHST- 2022/08/12 06:00 [medline]
PHST- 2022/01/12 06:13 [entrez]
AID - 327236 [pii]
AID - 10.4103/ijc.IJC_71_20 [doi]
PST - ppublish
SO  - Indian J Cancer. 2022 Apr-Jun;59(2):251-256. doi: 10.4103/ijc.IJC_71_20.